

1        **Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and**  
2        **Omicron by mRNA vaccination and infection-derived immunity through homologous and**  
3        **heterologous variants**

4

5 Meriem Bekliz<sup>1</sup>, Kenneth Adea<sup>1</sup>, Pauline Vetter<sup>2,3</sup>, Christiane S Eberhardt<sup>4,5,6</sup>, Krisztina Hosszu-  
6 Fellous<sup>2,3</sup>, Diem-Lan Vu<sup>2</sup>, Olha Puhach<sup>1</sup>, Manel Essaidi-Laziosi<sup>1</sup>, Sophie Waldvogel-Abramowski<sup>7</sup>,  
7 Caroline Stephan<sup>7</sup>, Arnaud G. L'Huillier<sup>8</sup>, Claire-Anne Siegrist<sup>4</sup>, Arnaud M Didierlaurent<sup>4</sup>, Laurent  
8 Kaiser<sup>2,3</sup>, Benjamin Meyer<sup>4\*</sup>, Isabella Eckerle<sup>1,2,3\*</sup>

9

10 <sup>1</sup>Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

11 <sup>2</sup>Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva  
12 1205, Switzerland.

13 <sup>3</sup>Geneva Centre for Emerging Viral Diseases, Geneva, University Hospital and Faculty of Medicine,  
14 Geneva, Switzerland.

15 <sup>4</sup>Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology,  
16 University of Geneva, Switzerland

17 <sup>5</sup>Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of  
18 Medicine, University of Geneva

19 <sup>6</sup>Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland

20 <sup>7</sup>Transfusion Unit, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

21 <sup>8</sup>Pediatric Infectious Diseases Unit, Department of Women, Child and Adolescent Medicine, Geneva  
22 University Hospitals and Faculty of Medicine, Geneva, Switzerland.

23

24 *\*Corresponding authors:*

25 Isabella Eckerle,

26 Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.

27 Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.

28 Tel: +41223729820;

29 Email: [isabella.eckerle@hcuge.ch](mailto:isabella.eckerle@hcuge.ch)

30

31 Benjamin Meyer

32 Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Switzerland.

33 Rue Michel-Servet 1, 1211 Geneva 4, Switzerland

34 Tel: +41 22 379.57.80

35 Email: [Benjamin.Meyer@unige.ch](mailto:Benjamin.Meyer@unige.ch)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 **Abstract**

37 Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of  
38 neutralizing antibodies derived from infection or vaccination. As the population immunity to SARS-CoV-  
39 2 has become more complex due to prior infection and/or vaccination, understanding the antigenic  
40 relationship between variants is needed.

41 Here, we have assessed in total 104 blood specimens from convalescent individuals after infection with  
42 early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post-vaccination after  
43 double-dose mRNA-vaccination and break through infections due to Delta or Omicron. Neutralization  
44 against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was  
45 assessed by plaque-reduction neutralization assay.

46 We found highest neutralization titers against the homologous (previously infecting) variant, with lower  
47 neutralization efficiency against heterologous variants. Significant loss of neutralization for Omicron was  
48 observed but to a varying degree depending on previously infecting variant (23.0-fold in Beta-  
49 convalescence up to 56.1-fold in Alpha-convalescence), suggesting that infection-derived immunity  
50 varies, but independent of the infecting variant is only poorly protective against Omicron. Of note, Zeta  
51 VOI showed also pronounced escape from neutralization of up to 28.2-fold in Alpha convalescent  
52 samples. Antigenic mapping reveals both Zeta and Omicron as separate antigenic clusters.

53 Double dose vaccination showed robust neutralization for Alpha, Beta, Gamma, Delta and Zeta, with  
54 fold-change reduction of only 2.8 (for Alpha) up to 6.9 (for Beta). Escape from neutralization for Zeta  
55 was largely restored in vaccinated individuals, while Omicron still showed a loss of neutralization of  
56 85.7-fold compared to pre-VOC SARS-CoV-2.

57 Combined immunity from infection followed by vaccination or vaccine breakthrough infection showed  
58 highest titers and most robust neutralization for heterologous variants. Breakthrough infection with Delta  
59 showed only 12.5-fold reduced neutralization for Omicron, while breakthrough infection with Omicron  
60 showed only a 1.5-fold loss for Delta, suggests that infection with antigenically different variants can  
61 boost immunity for antigens closer to the vaccine strain. Antigenic cartography showed also a tendency  
62 towards broader neutralizing capacity for heterologous variants.

63 We conclude that the complexity of background immunity needs to be taken into account when  
64 assessing new VOCs. Development towards separate serotypes such as Zeta was already observed  
65 before Omicron emergence, thus other factors than just immune escape must contribute to Omicrons  
66 rapid dominance. However, combined infection/vaccination immunity could ultimately lead to broad  
67 neutralizing capacity also against non-homologous variants.

68 **Keywords**

69 SARS-CoV-2, COVID19, variants of concern, Alpha, Beta, Gamma, Delta, Zeta, Omicron, PRNT,  
70 neutralization, vaccination

## 71 Introduction

72 In late 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan  
73 (China) causing a pandemic that led to an unprecedented international health crisis of yet unknown  
74 outcome [1, 2]. Shortly after its emergence, SARS-CoV-2 acquired the D614G mutation in the spike  
75 protein in February 2020, which quickly replaced all other circulating variants and spread worldwide.  
76 The evolutionary advantage of D614G is associated with enhanced binding to the human receptor and  
77 increased replication and thus presumably better transmissibility [3]. After largely uncontrolled  
78 transmission on a global scale during 2020, the emergence of the first variants of concern (VOCs) was  
79 observed [4]. The VOCs consist of the Alpha variant, first detected in the UK; the Beta variant, first  
80 detected in South Africa, the Gamma variant, first detected in South America, the Delta variant, first  
81 detected in India and the Omicron variant, very recently reported from South Africa [5]. Variants of  
82 concern were characterized by a rapid increase in case numbers and they quickly outcompeted earlier  
83 strains in their region of emergence. The latest emergence is the Omicron variant in late 2021 with the  
84 so far highest number of mutations compared to earlier variants and the majority of them located in the  
85 spike protein [4]. Thus, suspicion of escape from antibody responses derived from earlier variants and  
86 vaccines by Omicron is high.

87 In addition to VOCs, other variants were identified that were of less concern and therefore classified as  
88 variants of interest (VOI) due to aspects in their epidemiology or genetic signatures potentially leading  
89 to an altered phenotype, among them the (former) VOI Zeta that arose in parallel with the Gamma  
90 variant in South America at a time when a local surge in cases was observed but has disappeared in  
91 the meantime [6-10].

92 Currently, few treatments are widely available for SARS-CoV-2 and mostly dedicated to risk groups,  
93 therefore prevention and protection through vaccine-mediated immunity is still the proposed method for  
94 ending the pandemic [11]. Depending on countries, medium to high levels of population immunity have  
95 already been reached through vaccination or infection, but there are huge geographical differences  
96 when it comes to the proportions of the population infected, different circulation of variants against which  
97 immunity was obtained, percentage of vaccinated individuals, vaccine doses and type of vaccine used.  
98 In light of that, it is of particular importance to evaluate the neutralizing potential of elicited antibodies  
99 against clinical isolates of VOCs/VOIs to detect immune escape variants early and understand the  
100 impact of such variants on the further course of the pandemic.

101 The mRNA-based vaccine Pfizer-BioNTech BNT162b2 encodes a stabilized full-length SARS-CoV-2  
102 spike ectodomain derived from the Wuhan-Hu-1 genetic sequence and elicits potent neutralizing  
103 antibodies [12], as does the mRNA-based vaccine Moderna mRNA-1273 [13]. However, emerging  
104 SARS-CoV-2 variants include multiple substitutions and deletions in the major target of neutralizing  
105 antibodies, the spike glycoprotein, including the N-terminal (NTD) and the receptor-binding domains  
106 (RBD), with the largest number of mutations of over 30 observed in the Omicron variant. This raises the  
107 question of whether neutralizing antibodies induced by early circulating strains or by current vaccines  
108 can effectively neutralize recently emerged virus variants. So far, studies indicated that mutations that  
109 have been accumulating in the spike protein, especially in the RBD, are associated with increased  
110 affinity to the human ACE2 receptor [14], as well as with resistance to neutralization from antibodies of

111 previously infected or vaccinated patients [15]. Mutations in the RBD pose the greatest risk for making  
112 SARS-CoV-2 more infectious and able to escape antibody neutralization [14]. Virus neutralizing  
113 antibody have been shown to be a correlate of protection from SARS-CoV-2 but more insights on  
114 neutralizing responses against emerging virus variants are needed [16-19].

115 In this study, we investigated the neutralizing potency of a panel of authentic sera or plasma from  
116 individuals vaccinated twice with either BNT162b2 or mRNA-1273, and convalescent patients that had  
117 mild coronavirus disease 2019 (COVID-19). Patients were infected at different time points during the  
118 pandemic with either an early-pandemic (pre-VOC) SARS-CoV-2 or one of the VOCs Alpha, Beta,  
119 Gamma, Delta or Omicron. We used authentic clinical isolates for pre-VOC SARS-CoV-2 (Pangolin  
120 lineage B.1), Alpha, Beta, Gamma, Delta, Zeta and Omicron which were all isolated from patient  
121 samples collected from our routine diagnostic laboratory. We assessed the neutralizing potential  
122 against homologous and heterologous variants by live virus plaque reduction neutralization test  
123 (PRNT), widely regarded as the gold standard for the detection of SARS-CoV-2-specific neutralizing  
124 antibodies [20].

## 125 **Materials and Methods**

### 126 **Setting**

127 The laboratory of virology of the University Hospital of Geneva is participating and coordinating the  
128 SARS-CoV-2 variant and genomic surveillance funded by the Swiss Federal Office of Public Health  
129 with constantly ongoing full genome sequencing of SARS-CoV-2 positive patient samples obtained  
130 through the diagnostic unit of our Centre [21]. Up to around 400 positive patient specimens with a cycle  
131 threshold (Ct) < 32 are sequenced each week since march 2021. From each variant that falls into any  
132 of the categories of variant of concern/interest, at least one virus isolate is generated.

### 133 **Patient samples**

134 Convalescent sera or plasma during the early pandemic period (pre-VOC) were collected in the context  
135 of two prospective cohort studies at the Geneva University Hospitals (HUG) and the Geneva Centre for  
136 Emerging Viral Diseases (Understanding COVID study; ethics approval number: CCER 2020-00516,  
137 Persistence study: ethics approval number: CCER 2020-00516). In addition, anonymized left-over  
138 samples from apheresis collection of plasma (all collected in 2020) were available under the general  
139 informed consent of the University Hospitals of Geneva.

140 Convalescent sera obtained from patients infected with a SARS-CoV-2 variant of concern (Alpha, Beta,  
141 Gamma, Delta, Omicron) were collected in 2021 by contacting patients with confirmed SARS-CoV-2  
142 infection for a blood collection in the convalescent period for the purpose of this study, same for vaccine  
143 breakthrough infections (Ethics approval number: CCER 2020-02323). For each patient infected with a  
144 variant, information on the infecting virus was available by full-genome sequence. No sequence  
145 information on the infecting strain was available from patients infected in 2020, however the first SARS-  
146 CoV-2 variant in Switzerland (Alpha) was only observed on Dec 24, 2020, and all pre-VOC samples  
147 were collected before that date, thus they are considered pre-VOC. Plasma samples from vaccinated

148 healthy individuals, vaccinated with 2 doses of BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna)  
149 vaccine at 28 days interval were available from a prospective observational study, collected 30 days  
150 after the 2<sup>nd</sup> dose (Ethics approval number: CCER ICOVax 2021-00430).  
151 Convalescent samples were only collected from individuals with RT-PCR-confirmed diagnosis of SARS-  
152 CoV-2 in our diagnostic unit, and sera/plasma were collected 3-137 days after diagnosis or symptom  
153 onset (days post diagnosis, DPP). All vaccinated individuals were in addition tested for the presence of  
154 nucleocapsid antibodies (Elecsys® Anti-SARS-CoV-2 anti-N) to screen for unrecognized infection prior  
155 to vaccination. There are no differences to be expected in the PRNT regarding the use of plasma or  
156 serum, therefore both sample types are used in parallel and termed “convalescent samples” throughout  
157 the manuscript.

### 158 **Viruses and cells.**

159 Vero-E6 and Vero E6-TMPRSS cells were cultured in complete DMEM GlutaMax I medium  
160 supplemented with 10% fetal bovine serum, 1x Non-essential Amino Acids, and 1% antibiotics  
161 (Penicillin/Streptomycin) (all reagents from Gibco, USA). Vero-TMPRSS were kindly received from  
162 National Institute for Biological Standards and Controls (NIBSC, Cat. Nr. 100978).

163 All SARS-CoV-2 viruses used in this study were isolated from residual nasopharyngeal swabs collected  
164 from patients presenting at the Geneva University Hospitals under general informed consent of the  
165 hospital that allows usage of anonymized left-over materials. All patient specimens from which isolates  
166 were obtained were fully sequenced (**Table S1**). The following viruses were isolated as follows: B.1,  
167 Alpha, Gamma and Zeta were isolated and propagated on Vero E6. The Beta variant isolate was  
168 obtained as described previously [22]. Briefly, no primary Beta isolate could be obtained on VeroE6 but  
169 only on A549 cells overexpressing human ACE2 [23]. Therefore, after primary isolation, A549-hACE2  
170 cells were mixed with VeroE6 in a 1:1 ratio and inoculated with the passage 1 isolate. The next passage  
171 was done on VeroE6 to generate the virus stock. The Omicron variant was primarily isolated on Vero-  
172 TMPRSS cells, then transferred to Vero E6 for generation of a virus stock. All virus stocks were titrated  
173 on Vero-E6 cells and full genome sequenced. Sequences of initial patient specimens and virus isolates  
174 obtained were compared for acquired mutations. Experiments with live infectious SARS-CoV-2 followed  
175 the approved standard operating procedures of our biosafety level 3 facility (BSL-3).

### 176 **Plaque Reduction Neutralization Test (PRNT).**

177 Following the PRNT procedure, Vero-E6 cells were seeded at a density of  $4 \times 10^5$  cells/mL in 24-well cell  
178 culture plates. A total of 34, 12, 8, 10 and 22 sera/plasma samples from patients infected with pre-VOC  
179 SARS-CoV-2, Alpha, Beta Gamma, Delta or sera from individuals vaccinated with BNT162b2/mRNA-  
180 1273, respectively, were used for determining the neutralizing titers against B.1 (first pandemic wave  
181 strain containing only the D614G substitution in the spike gene), Alpha, Beta, Gamma, Zeta, Delta and  
182 Omicron variants as described earlier [24]. Briefly, all sera/plasma were heat-inactivated at 56°C for 30  
183 min and serially diluted in Opti-Pro serum-free medium starting from 1:10 until up to 1:5120 if necessary.  
184 Sera/plasma were mixed with 50PFU of variant isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta and  
185 Omicron) and incubated at 37°C for 1h. All samples were run in duplicate and for each neutralization  
186 experiment an infection control (no serum/plasma) and a reference serum were used to ensure

187 reproducibility between different experiments. Vero-E6 cells were washed 1x with PBS and inoculated  
188 with the virus serum/plasma mixture for 1h. Afterwards, the inoculum was removed and 500uL of the  
189 overlay medium also used for the plaque assays was added. After incubation for 3 days at 37°C, 5%  
190 CO<sub>2</sub>, the overlay medium was removed, cells were fixed in 6% formaldehyde solution for at least 1h,  
191 plates were washed 1x with PBS and stained with crystal violet. Plaques were counted in wells  
192 inoculated with virus- serum/plasma mixtures and compared to plaque counts in infection control wells.  
193 The 90% reduction endpoint titers (PRNT<sub>90</sub>) were calculated by fitting a 4-parameter logistics curve with  
194 variable slope to the plaque counts of each serum/plasma using GraphPad Prism version 9.2.0. For  
195 samples that did not reach 90% reduction at a 1:10 dilution, we extrapolated the titer until a dilution of  
196 1, i.e. undiluted sample. If the extrapolation reached a titer below 1, the sample was given a value of  
197 0.5 and considered negative.

198

### 199 **Antigenic cartography**

200 Antigenic maps were constructed with the software from <https://acmacs-web.antigenic-cartography.org>.  
201 The maps were generated with PRNT<sub>90</sub> titers obtained for convalescence specimens from pre-VOC  
202 SARS-CoV-2, Alpha, Beta, Gamma and Delta and for post-vaccine specimens with and without prior  
203 infection, as described previously [25]. Breakthrough infections with Delta and Omicron were not  
204 included due to low number of samples.

205

### 206 **Statistical analysis**

207 Geometric means with 95% CI were used for comparison of PRNT<sub>90</sub> titers. All statistical analyses were  
208 conducted using GraphPad Prism version 9.1.0 software, performed using log<sub>10</sub> ANOVA transformed  
209 PRNT<sub>90</sub> titers. Results were considered significant with p values <0.05.

## 210 **Results**

211 To evaluate the neutralization capacity of SARS-CoV-2 specific antibodies against SARS-CoV-2  
212 variants (pre-VOC, Alpha, Beta, Gamma, Delta, Zeta and Omicron), a panel of convalescent blood  
213 specimens were used from i) individuals previously infected with pre-VOC SARS-CoV-2 (n=34), ii)  
214 individuals previously infected with VOCs Alpha (n=12), Beta (n=8), Gamma (n=10), Delta (n=10) iii)  
215 BNT162b2 or mRNA-1273 vaccinated individuals with (n=6) and without prior infection (n=16) iv)  
216 BNT162b2 or mRNA-1273 vaccinated individuals with a break-through infection with either Delta (n=4)  
217 or Omicron (n=4) (**Table 1**).

### 218 *Neutralizing capacity from infection-derived convalescent samples*

219 Geometric mean PRNT<sub>90</sub> titers of convalescent specimens from individuals infected with pre-VOC  
220 SARS-CoV-2 were 37.3 (95%CI: 25.4-54.9) against B.1, 16.7 (95%CI: 9.7-28.8) against Alpha, 14.0  
221 (95%CI: 8.8-22.3) against Beta, 10.3 (95%CI:6.4-16.6) against Gamma, 12.0 (95%CI:7.0-20.3) against  
222 Delta, 1.4 (95%CI: 0.9-2.4) against Zeta, and 0.8 (95%CI:0.6-1.2) against Omicron. Compared to B.1  
223 this results in a fold-change reduction of 2.2 for Alpha, 2.7 for Beta, 3.6 for Gamma, 3.1 for Delta, 25.9



224 for Zeta and 45.6 for Omicron (**Figure 1A**). None of the samples failed to neutralize the homologous  
225 virus. Only 1/34 (3%), 2/34 (6%), 3/34 (9%) and 3/34 (9%) failed to neutralize Alpha, Beta, Gamma and  
226 Delta, respectively, whereas 21/34 (62%) and 29/34 (85%) completely failed to neutralize the Zeta and  
227 Omicron variant.

228 For patients previously infected with the Alpha variant (n=12), geometric mean PRNT<sub>90</sub> titers were 45.5  
229 (95%CI:34.3-60) for Alpha, 27.8 (95%CI:19.8-39.0) for B.1, 7.4 (95%CI:4.0-13.5) for Beta, 3.8  
230 (95%CI:1.6-8.7) for Gamma, 5.9 (95%CI:2.8-12.2) for Delta, 1.6 (95%CI:0.7-3.6) for Zeta and 0.8  
231 (95%CI:0.4-1.7) for Omicron. Compared to the homologous Alpha variant, this results in a reduction of  
232 1.6 (B.1), 6.2 (Beta), 12.0 (Gamma), 7.7 (Delta), 28.2 (Zeta) and 56.1 (Omicron). Complete loss of  
233 neutralization was observed for 3/12 (25%) samples for Gamma, 1/12 (8%) for Delta, 5/12 (42%) for  
234 Zeta and 10/12 (83%) for Omicron (**Fig. 1B**).

235  
236 For individuals previously infected with the Beta variant (n=8), geometric mean PRNT<sub>90</sub> titers were 20.6  
237 (95%CI:6.8-62.6) for Beta, 6.0 (95%CI:1.3-27.2) for B.1, 2.6 (95%CI:0.4-14.9) for Alpha, 2.6  
238 (95%CI:0.4-15.8) for Gamma, 3.2 (95%CI:0.7-15.3) for Delta, 1.7 (95%CI:0.4-7.5) for Zeta and 0.9  
239 (95%CI:0.4-2.3) for Omicron. Compared to the homologous virus (Beta), this results in a fold-reduction  
240 of 3.5 for B.1, 8.0 for Alpha, 7.8 for Gamma, 6.4 for Delta, 12.4 for Zeta and 23.0 for Omicron. Complete  
241 loss of neutralization was observed for 1/8 (12.5) for B.1, 4/8 (50%) for Alpha, 4/8 (50%) for Gamma,  
242 3/8 (37.5) for Delta, 4/8 (50%) for Zeta and 6/8 (75%) for Omicron (**Fig. 1C**).

243  
244 For individuals previously infected with the Gamma variant (n=10), geometric mean PRNT<sub>90</sub> titers were  
245 55.6 (95%CI:24.1-128) for Gamma, 20.5 (95%CI:7.6-55.5) for B.1, 13.9 (95%CI:5.9-32.9) for Alpha,  
246 18.3 (95%CI:8.9-37.4) for Beta, 3.2 (95%CI:1.0-10.1) for Delta, 10.2 (95%CI:5.2-20.2) for Zeta and 2.1  
247 (95%CI:0.7-6.4) for Omicron. Compared to the homologous virus, fold reduction in neutralization was  
248 2.7 for B.1, 4.0 for Alpha, 3.0 for Beta, 17.6 for Delta, 5.4 for Zeta and 26.9 for Omicron. Complete loss  
249 of neutralization was observed for 4/10 (40%) for Delta and 5/10 (50%) for Omicron (**Fig. 1D**). Of note,  
250 a rather strong loss of neutralization in Gamma convalescent samples was observed for Delta, while  
251 neutralization was less affected for the Zeta variant.

252  
253 For individuals previously infected with Delta (n=10), geometric mean PRNT<sub>90</sub> titers were 72.8  
254 (95%CI:33.9-156.2) for Delta, 25.1 (95%CI:14.0-45.1) for B.1, 18.4 (95%CI:9.5-35.4) for Alpha, 13.2  
255 (95%CI:7.4-23.5) for Beta, 15.0 (95%CI:7.8-28.7) for Gamma, 10.4 (95%CI:4.0-26.9) for Zeta and 3.1  
256 (95%CI:1.0-9.6) for Omicron. Fold reduction compared to homologous virus (Delta) was 2.9 for B.1, 4.0  
257 for Alpha, 5.5 for Beta, 4.9 for Gamma, 7.0 for Zeta and 23.8 for Omicron. Complete loss of  
258 neutralization was 1/10 (10%) for Zeta and 4/10 (40%) for Omicron (**Fig. 1E**).

259  
260 A heatmap for fold-change reduction of neutralization was generated to summarize findings across all  
261 convalescent specimens (**Fig. 1F**). Here, rather robust neutralization of pre-VOC convalescent  
262 specimens against VOCs Alpha, Beta, Gamma and Delta is visible while the other variants showed

263 stronger escape from immunity against heterologous variant. Immune escape properties for Zeta and  
264 Omicron are visible, with stronger immune escape of Zeta from pre-VOC and Alpha immunity, but less  
265 from Gamma and Delta immunity. Immune escape of Omicron was pronounced throughout all  
266 specimens, although the fold-change reduction is in a comparable range to that of Zeta for some  
267 combinations.

#### 268 *Neutralizing capacity from post-vaccine and combined post-vaccine/infection-derived samples*

269 We investigated a total of 30 patient specimens from either double-vaccinated individuals (n=16) or with  
270 combined vaccination-infection-derived immunity, either through prior infection followed by vaccination,  
271 or vaccination followed by a vaccine breakthrough infection with Delta or Omicron (n=14).

272

273 In contrast to all infection-derived convalescent samples, geometric mean PRNT<sub>90</sub> titers were much  
274 higher for individuals double-vaccinated with either BNT162b2 or mRNA-1273 with titers of 338.0  
275 (95%CI:247.4-461.6) against B.1, 121.7 (95%CI:86.0-172.3) against Alpha, 49.3 (95%CI:28.1-86.8) for  
276 Beta, 62.8 (95%CI:36.0-109.5) for Gamma, 95.6 (95%CI:69.4-131.7) for Delta, 78.5 (95%CI:50.4-  
277 122.5) for Zeta and 3.9 (95%CI:1.8-8.7) for Omicron. This translates into a fold reduction of  
278 neutralization of 2.8 for Alpha, 6.9 for Beta, 5.4 for Gamma, 3.5 for Delta, 4.3 for Zeta and 85.7 for  
279 Omicron. No complete loss of neutralization was seen for any VOC except Omicron in 5/16 (31%)  
280 specimens (**Fig. 2A**).

281

282 Individuals with prior SARS-CoV-2 infection before double vaccination (n=6), as determined by  
283 presence of antibodies against the nucleocapsid, showed geometric mean PRNT<sub>90</sub> titers of 1190.4  
284 (95%CI:837.8-1691) against B.1, followed by 683.2 (95%CI:516.3-904.1) for Alpha, 260.4  
285 (95%CI:128.8-526.5) for Beta, 360.4 (95%CI:224.5-578.5) for Gamma, 494.1 (95%CI:419.4-582.1) for  
286 Delta, 351.8 (95%CI:227-545.2) for Zeta and 65.2 (95%CI:27.81-153.0) for Omicron. Fold reduction in  
287 neutralization was 1.7 for Alpha, 4.6 for Beta, 3.3 for Gamma, 2.4 for Delta, 3.4 for Zeta and 18.2 for  
288 Omicron. Of note, none of the specimens showed complete loss of neutralization (**Fig. 2B**).

289

290 In addition, we have investigated vaccinated individuals with a breakthrough infection with Delta (n=4)  
291 and Omicron (n=4) for neutralization against both viruses which are currently the only VOCs co-  
292 circulating. For the first group, high geometric mean PRNT<sub>90</sub> titers of 1636 (95%CI: 128.2-20885) were  
293 observed for the Delta while 130.9 (95%CI:24.9-688.9) was observed for Omicron. This results in a  
294 12.5-fold reduction versus the homologous Delta, but no complete loss of neutralization was observed  
295 (**Fig. 2C**). For Omicron breakthrough infections following vaccination, geometric mean PRNT<sub>90</sub> titers of  
296 913.5 (95%CI:341.8-2442) were observed for Omicron, and 627.9 (95%CI:269.5-1463) were observed  
297 for Delta, which equals a 1.5-fold loss of neutralization to heterologous Delta (**Fig. 2D**). Highest titers  
298 were seen against the infecting variant Omicron compared to Delta, although the prior vaccine-derived  
299 immunity by an early pandemic spike is antigenically closer to Delta than to Omicron.

300



301 A heatmap of fold-change reduction of neutralization was performed to summarize findings across all  
302 post-vaccine and combined infection/vaccine specimens (**Fig. 2E**). The pronounced escape from  
303 vaccination specific for Omicron is visible here, while much less immune escape was observed for the  
304 other VOCs as well as for Zeta. Neutralization for Omicron is improved in all specimens with combined  
305 infection/vaccination immunity.

306

307 We also performed a mapping of our titration results using antigenic cartography (**Fig. 3**). Here we could  
308 show that homologous sera cluster around the respective infecting virus, with Alpha and pre-VOC  
309 specimens clustering together most closely. Earlier variants of concern before Omicron (Alpha, Beta,  
310 Gamma, Delta) belong to one antigenic cluster. Zeta and Omicron are more distantly represented in  
311 the map with more than 3 units distance to all other viruses, thus presenting two separate antigenic  
312 clusters (**Fig. 3A**). Post vaccine sera cluster around B.1 and Alpha strains, and a larger but equal  
313 distance to Beta and Gamma is observed (**Fig. 3B**). Again, Zeta shows a larger antigenic distance, but  
314 Omicron is the most distant. Of note, specimens with combined immunity from infection followed by  
315 vaccination are located closer to the other non-Alpha VOCs compared to post-vaccination samples  
316 without prior infection.

317

318 *Individual profiles of SARS-CoV-2 homologous and heterologous neutralization*

319

320 In addition to cumulated data (**Fig. 1 and 2**), neutralization profiles were also displayed on an individual  
321 basis (**Figure S1-S9**). Here, inter-individual differences both in quantity of antibody response as well as  
322 patterns of neutralization loss towards heterologous variants were observed, which does not  
323 necessarily reflect pooled results in all individuals. For example, while neutralization against Omicron  
324 was the lowest throughout convalescent samples, the differences between Alpha, Beta and Gamma  
325 were less pronounced in some individuals. Of note, in all individual comparisons, the most efficient  
326 neutralization was always observed against the homologous (infecting) strain through all convalescent  
327 sera as well as vaccine sera, when considering that the vaccine Spike most closely resembles the early  
328 pandemic variant B.1.

329

## 330 **Discussion**

331 Here we assess neutralizing capacity towards seven SARS-CoV-2 variants by convalescent specimens  
332 from individuals recovered from infection with the early-pandemic strain (pre-VOC) or the VOCs Alpha,  
333 Beta, Gamma or Delta, from double-vaccinated individuals either with or without prior infection and from  
334 double-vaccinated individuals infected with the Delta or Omicron variant.

335 We could show that highest SARS-CoV-2 neutralizing titers, either elicited through infection of  
336 vaccination, were always observed against the homologous strain (infecting strain or antigen used in  
337 the vaccine formulation), whereas a reduced neutralizing capacity was found for heterologous strains.

338 In agreement with our results, one study found lower neutralization for the Alpha and Gamma variant  
339 by pre-VOC convalescent sera and lower neutralization for pre-VOC and Alpha in Gamma infected  
340 patients, but reduced neutralization only for Gamma in vaccine sera [26]. In line with these  
341 observations, Alpha-infected individuals showed reduced neutralization for the Beta variant [27].  
342 Reduction in neutralization capacity for the Delta variant was estimated between 4- and 8-fold in  
343 vaccinated and 6-fold in convalescent sera [28]. Beyond our study, there is one pre-print that  
344 investigated the response to VOCs in a background of variant-specific convalescent samples from  
345 individuals infected with pre-VOC, Alpha, Beta or Delta samples, that showed strongest neutralization  
346 towards homologous vs heterologous virus for Alpha, Beta and Delta convalescent-variant pairs. [29]

347 We observed a reduction of neutralization capacity by first-wave SARS-CoV-2 convalescent and post-  
348 vaccine samples towards Alpha, Beta, Gamma and Delta to a comparable extent than what was  
349 described by others [28, 30-33]. In comparison with neutralizing activity of other convalescent samples,  
350 pre-VOC specimens induced immunity showed rather robust neutralization against Alpha, Beta,  
351 Gamma and Delta, while convalescent specimens from VOC infections showed lower potential to  
352 neutralize heterologous viruses. While for the Alpha variant, only slightly reduced neutralization was  
353 described for both convalescent and vaccinee sera, a more pronounced reduction of neutralization was  
354 observed for the Beta and Gamma variant [31, 32, 34-37]. Thus, Beta and Gamma comprised the two  
355 VOCs with the most pronounced immune escape and at the same time successful enough to cause  
356 larger outbreaks in defined geographic region, without reaching global dominance in the time before  
357 the emergence of Omicron. A recent study with pre-VOC SARS-CoV-2, Alpha and Beta in multiple  
358 animal and cell culture models showed enhanced fitness of Alpha but not Beta which could be a reason  
359 why Alpha but not Beta reached wide dominance in early 2021 [22].

360 Across our panel of convalescent and vaccine sera, the strongest decline of neutralization capacity was  
361 observed for Zeta and Omicron. While convalescent specimens showed strong reduction of  
362 neutralization for Zeta of up to 25.9-fold, neutralization capacity was restored in vaccinated individuals  
363 that showed only 4.3-fold decline compared to pre-VOC SARS-CoV-2. In contrast, for Omicron, a stark  
364 loss of neutralizing activity of up to 46-fold or 86-fold was observed for both convalescent and vaccine  
365 sera, respectively. Thus, fold-change reduction was even higher in vaccine sera than in convalescent  
366 sera, although titer in vaccine sera were higher and therefore percentage of specimens with complete  
367 loss was lower (31% of specimens vs. 83%). A similar loss of neutralization capacity against Omicron  
368 was observed in other studies [29, 38-40], although no validation across the full range of VOC  
369 convalescent sera was available before our data set. Interestingly, strongest loss of neutralization for  
370 Zeta was in a similar range to the weakest loss of neutralization for Omicron, e.g. a 25.9-fold reduction  
371 of Zeta in pre-VOC convalescent samples, and a 23.0-fold reduction of Omicron in Beta convalescent  
372 samples. Such observed differences in fold-change reduction between Zeta and Omicron were less  
373 than 2-fold in pre-VOC, Alpha and Beta convalescent sera, showing that even before the emergence  
374 of Omicron, variants with strong immune escaping properties almost reaching that of Omicron were  
375 already circulating but did not become dominant. For post-Gamma and post-Delta specimens, the  
376 differences between fold-change reduction of Zeta and Omicron were much bigger, with Omicron

377 showing a 3-5-fold higher escape of neutralization compared to Zeta. At least for Gamma, robust  
378 neutralization for Zeta could be explained by a common origin as both are descendants from B.1.1.28  
379 (Pango lineage) [10]. To the best of our knowledge, no data on neutralization of the Zeta variant by  
380 convalescent or vaccinee samples has been described to date, and few other data were obtained on  
381 this variant. Contrary, loss of neutralization for Delta was much more pronounced in Gamma than in  
382 any other convalescent or vaccine sera with a 17.6-fold reduction. Such strong immune escape of Delta  
383 in a variant-specific infection background has not been reported before.

384 A recent preprint mapped antigenic diversity of SARS-CoV-2, a method that was originally developed  
385 to map antigenic relationship for influenza viruses by hemagglutinin inhibition assay [25, 41]. When  
386 used to assess influenza viruses, one unit represents a 2-fold change in neutralization titer, and a  
387 distance of more than 3 units is required for a separate antigenic cluster, while below 3, it is  
388 considered antigenically similar. They show that ancestral SARS-CoV-2, Alpha, Beta, Gamma and  
389 Delta form one antigenic cluster, while Omicron forms a separate antigenic cluster. Differences to our  
390 study was that neutralization in this study was only done with a pseudovirus assay and with a lower  
391 number of convalescent samples from patients infected with VOCs. Upon analysis for antigenic  
392 cartography, our data confirm the findings of Omicron as another antigenic cluster by full virus PRNT,  
393 but in addition for the first time we could also show Zeta forms a separate antigenic cluster [25].  
394 Furthermore, we can show that combined immunity after infection/vaccination shows a reduced  
395 distance to heterologous variants such as Beta, Gamma and Delta in the map when compared to  
396 vaccine samples without additional infection, indicative of broader neutralization.

397 Of note, we have observed large differences in the reduction of neutralization capacity across  
398 specimens with different infection background which has not been described in this detail before. While  
399 convalescent specimens of individuals infected with a pre-VOC SARS-CoV-2 and Alpha showed 45.6-  
400 and 56.1-fold reduction of neutralization capacity for Omicron, patients previously infected with the Beta,  
401 Gamma or Delta variant showed a lower reduction in neutralization capacity of 23.0, 26.9 and 23.8-fold,  
402 and a lower percentage of specimens with complete neutralization failure, respectively. These  
403 differences could indicate that regional heterogeneity in background immunity could potentially  
404 influence emergence and spread of Omicron or other future variants with immune escape properties.

405 A gradient of immune escape can be described from the variants investigated here, from pre-VOC to  
406 Alpha (only slight immune escape, but successfully outcompeted earlier strains), Beta and Gamma  
407 (more pronounced immune escape with regionally pronounced circulation but no global dominance) to  
408 Zeta (variant with one of the strongest escapes of immunity prior to Omicron, but limited transmission).  
409 Our data on Zeta, along with data two other VOIs Mu and Lambda, have shown the strongest escape  
410 from neutralization in pandemic period before the emergence of Omicron [42-45]. Although differences  
411 between escape from neutralization between Zeta and Omicron are only two-fold in some subgroups,  
412 neutralization for Zeta was restored in vaccinee specimens, while this was not the case for Omicron.  
413 This could hint towards different mechanisms of immune escape between SARS-CoV-2 variants, and  
414 other fitness advantaged for Omicron beyond immune escape.

415 Of note, a mutation of position 484 in the receptor binding domain is found in Beta, Gamma, Zeta  
416 (E484K) and Omicron (E484A). The same mutation arose independently also in a lineage of the Alpha  
417 variant where it was also associated with escape from neutralizing antibodies [46]. It has been shown  
418 that a mutation at position 484 of the spike tends to have the strongest effect on receptor binding and  
419 neutralization [47-50]. While the mutation can explain, at least partly, the strong escape from  
420 neutralization in Omicron, it has no or only very low influence on ACE2-binding and is therefore most  
421 likely not associated with higher transmissibility, although the mechanism of transmissibility in Omicron  
422 is not well understood [51].

423 We have shown that Omicron exhibits a strong escape from neutralization in both convalescent and  
424 vaccine sera, although differences in fold change reduction exist depending on prior infection  
425 background. However, it has been shown that a third dose of a mRNA vaccine is able to restore  
426 neutralizing capacity [52-55]. Similarly, individuals with mixed immunity, i.e. infection prior to double  
427 vaccination, or infection after double vaccination, also leads to higher neutralizing capacity towards  
428 Omicron [29, 40]. With an increasing number of vaccine breakthrough infections observed during the  
429 Delta wave and reports of a large number of vaccine breakthrough infections with Omicron, an  
430 assessment of mixed immunity is of huge interest, especially for protection against new variants [56].  
431 In addition, it has been speculated whether the immune response towards an antigenically drifted  
432 SARS-CoV-2 variant will be influenced by pre-existing immunity [57].

433 Here we investigated four individuals with a Delta breakthrough infection after double vaccination and  
434 have found high neutralizing titers for Delta. Neutralization capacity for Omicron was markedly reduced,  
435 but titers were still higher than titers against other VOCs in double-vaccinated individuals indicating that  
436 even a boost with a mismatched strain (Delta) can lead to a considerable increase in immunity against  
437 Omicron. Similarly, vaccine breakthrough infections with Omicron resulted in very high neutralization  
438 titers against the Omicron variant indicating that infection with an antigenically drifted variant led to a  
439 robust Omicron-specific immune response despite the presence of pre-existing immunity against the  
440 original pandemic strain. Interestingly, neutralizing titers against the Delta variant were only minimally  
441 reduced compared to Omicron indicating that infection with antigenically different variants can boost  
442 immunity against variants that are antigenically similar to the vaccine strain.

443 Population immunity and evolutionary pressure might differ on a regional scale depending on the  
444 immunity induced by earlier circulating variants [58]. High titers of neutralizing antibodies, such as  
445 elicited by the vaccine, were at least partially able to neutralize earlier variants before the rise of  
446 Omicron. From an epidemiological point of view, this highlights that vaccine-induced immunity probably  
447 would have allowed lower virus circulation compared to immunity induced through infections, which  
448 may have prevented the evolution of new variants that harbor immune escape properties such as  
449 Omicron. Although the origin of Omicron is not well understood, it was speculated that a high  
450 background of Beta-variant immunity has favored the development of Omicrons immune escaping  
451 properties [59]. In contrast to earlier variants, Omicron is showing a rapid increase in cases with a short  
452 doubling time, in addition to its immune-escaping properties [60]. This, together with reduced

453 neutralization is also suggestive of decreased vaccine effectiveness, will further complicate the  
454 management of the pandemic.

455 Limitations of our study are the relatively low number of specimens that were available for convalescent  
456 specimens of patients previously infected with variants. Furthermore, we cannot exclude, that  
457 individuals infected with a VOC have not already been infected in 2020 with a first-wave virus and thus  
458 antibodies are derived from multiple infections with more than one variant. In addition, the Beta variant,  
459 which could not be readily isolated on VeroE6 cell lines had to be adapted to VeroE6 in order to be  
460 usable for our PRNT, thus the isolate accumulated mutations, which could affect the neutralization  
461 results. No convalescent samples were available from individuals infected with Zeta, and no  
462 convalescent samples were yet available from individuals infected with Omicron without prior  
463 vaccination. Furthermore, testing of single time points after infection/vaccination can only provide a  
464 snapshot and not inform on the duration of antibody responses over time. All our blood specimens were  
465 collected at rather early time points after infection or vaccination, thus with time, a broader neutralizing  
466 capacity towards the heterologous variant might be observed due to somatic hypermutation and affinity  
467 maturation, although in the case of Omicron most likely will not restore neutralization loss [61].

468 Overall, we could show that responses to variants before Omicron were associated with reduced, but  
469 not complete loss in neutralization both by infection-derived as well as vaccine derived immunity,  
470 although variants such as Zeta have already shown immune escape properties, but did not become  
471 dominant at the time of their emergence. Omicron, in contrast to earlier variants displays a strong  
472 immune escape with a surge in case numbers in many areas of the world. Furthermore, the continuous  
473 emergence of SARS-CoV-2 variants since late 2020 shows that the virus is still underlies evolutionary  
474 pressure and currently available vaccines might not be sufficient to mitigate the pandemic in the near-  
475 term future. Furthermore, whether immunity of a population was obtained by a vaccine or by previous  
476 infection with a certain SARS-CoV-2 variants could influence the type of evolutionary pressure for  
477 circulating SARS-CoV-2 and lead to the emergence of new variants that differ for countries with major  
478 vaccine vs. major infection-derived immunity.

479

## 480 **Acknowledgments**

481 We thank Pascale Sattouet-Roche for excellent technical help. We thank the staff of the laboratory of  
482 virology at the HUG for support. We thank all clinicians and technical staff responsible of the different  
483 clinical cohorts for their help. We are grateful for the patients who were willing to donate their samples  
484 and agree to participate in our research.

485 We thank Samuel Cordey and Florian Laubscher for help with sequence analysis. We thank Mirco  
486 Schmolke and Beryl Mazel-Sanchez for A549-hACE2 cells.

487 We thank Volker Thiel, Jenna Kelly and Silvio Steiner, Vetsuisse Bern, for help with Omicron  
488 sequencing.

489 **Funding**


490 This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National  
491 Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrege Bienfaisance du Groupe Pictet  
492 and the Fondation Privée des Hôpitaux Universitaires de Genève.



<b>Convalescent cohort</b>						
<b>Infecting virus</b>	<b>Number patient</b>	<b>Gender (M/F)</b>	<b>Age, mean</b>	<b>DPP/DPOS</b>	<b>Sample type</b>	<b>Infection period</b>
<b>pre-VOCs</b>	34	20/14	31	32 (25-37)*	Serum, Plasma	March-June 2020
<b>Alpha</b>	12	8/4	51	27 (8-42)	Serum	December 2020-February 2021
<b>Beta</b>	8	2/6	42	50 (3-98)	Serum	January-May 2021
<b>Gamma</b>	10	4/6	44	54 (7-137)	Serum	January-April 2021
<b>Delta</b>	10	4/6	42	71 (9-118)	Serum	May-July 2021
<b>Vaccinated cohort</b>						
<b>Vaccine</b>	<b>Number of patient</b>	<b>Gender (M/F)</b>	<b>Age mean</b>	<b>WPV Mean weeks (range)</b>	<b>Sample type</b>	<b>Date of vaccination</b>
<b>mRNA vaccine</b>	16	4/12	52	8	Serum, Plasma	March-May 2021
<b>Vaccinated and infected individuals</b>						
<b>Vaccination/infection status</b>	<b>Number of patient</b>	<b>Gender (M/F)</b>	<b>Age mean</b>	<b>WPV Mean weeks (range)</b>	<b>Sample type</b>	<b>Intervall vaccination – infection Mean weeks (range)</b>
<b>Prior infection + 2x vaccination</b>	6	3/3	46	n.a	Serum	n.a.
<b>2x vaccination + breakthrough (Delta)</b>	4	2/2	42	28 (16-37)	Serum	20 (11-28)
<b>2x vaccination + breakthrough (Omicron)</b>	2	1/1	49	26 (24-28)	Serum	23 (21-25)
<b>1x vaccination + breakthrough (Omicron)</b>	2	2/0	13	5 (5-5)	Serum	3 (3)

493 **Table 1.** Characteristic of sample cohorts used in this study. DPP, days post diagnosis, DPOS, days post symptom onset (marked with \*) WPV, weeks post  
494 2nd dose vaccination, n.a. not accessible


495 **Figures**



496


497 **Figure 1.** Neutralization in infection-derived blood specimens against seven authentic isolates of SARS-  
 498 CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent geometric mean titers  
 499 (GMT) of 90% reduction endpoint titers (PRNT<sub>90</sub>) with 95% confidence interval. Convalescent  
 500 specimens are derived from individuals infected with (A) early-pandemic SARS-CoV-2 (pre-VOC), (B)  
 501 Alpha (C) Beta (D) Gamma (E) Delta. Colored numbers above bars refer to fold change reduction of  
 502 GMT versus the homologous (infecting) variant, shown as first bar of each figure. Colored numbers  
 503 below each bar represents number of specimens with complete loss of neutralization (PRNT<sub>90</sub> titer < 1).  
 504 \*p < 0.05, \*\*p < 0.003, \*\*\*p < 0.0002 and \*\*\*\*p < 0.0001 (F) Heatmap of fold-reduction in neutralization  
 505 based on PRNT<sub>90</sub> data from A-E.

506



507

508 **Figure 2.** Neutralization in infection-derived blood specimens against seven authentic isolates of SARS-  
 509 CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent geometric mean titers  
 510 (GMT) of 90% reduction endpoint titers (PRNT<sub>90</sub>) with 95% confidence interval. Cohorts consist of  
 511 individuals with **(A)** double-dose mRNA vaccination, **(B)** prior SARS-CoV-2 infection followed by  
 512 double-dose mRNA vaccination **(C)** Delta breakthrough infection of double-vaccinated individuals and  
 513 **(D)** Omicron breakthrough infection following double (n=2) and single (n=2) mRNA vaccination. Colored  
 514 numbers above bars refer to fold change reduction of GMT versus the homologous (infecting) variant,  
 515 shown as first bar of each figure. Colored numbers below each bar represents number of specimens  
 516 with complete loss of neutralization (PRNT<sub>90</sub> titer < 1). \*p < 0.05, \*\*p < 0.003, \*\*\*p < 0.0002 and  
 517 \*\*\*\*p < 0.0001 **(F)** Heatmap of fold-reduction in neutralization based on PRNT<sub>90</sub> data from A-D.



518

519 **Figure 3.** Mapping of antigenic relationship using antigenic cartography for (A) convalescent specimens  
520 from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta infections and (B) all convalescent and  
521 post-vaccination specimens with and without prior infection. For graphical reasons only post vaccination  
522 specimens are shown in (B)

523

524 **References**

- 525 1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. N Engl J Med,  
526 2020. **382**(8): p. 727-733.
- 527 2. Zhou, P., et al., *A pneumonia outbreak associated with a new coronavirus of probable bat*  
528 *origin*. Nature, 2020. **579**(7798): p. 270-273.
- 529 3. Zhou, B., et al., *SARS-CoV-2 spike D614G change enhances replication and transmission*.  
530 Nature, 2021. **592**(7852): p. 122-127.
- 531 4. World Health Organization (WHO) 08.12.2021]; Available from:  
532 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
- 533 5. Viana, R., et al., *Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern*  
534 *Africa*. medRxiv, 2021: p. 2021.12.19.21268028.
- 535 6. Tegally, H., et al., *Detection of a SARS-CoV-2 variant of concern in South Africa*. Nature, 2021.  
536 **592**(7854): p. 438-443.
- 537 7. Davies, N.G., et al., *Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in*  
538 *England*. Science, 2021. **372**(6538).
- 539 8. Campbell, F., et al., *Increased transmissibility and global spread of SARS-CoV-2 variants of*  
540 *concern as at June 2021*. Euro Surveill, 2021. **26**(24).
- 541 9. Faria, N.R., et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*.  
542 Science, 2021. **372**(6544): p. 815-821.
- 543 10. Voloch, C.M., et al., *Genomic characterization of a novel SARS-CoV-2 lineage from Rio de*  
544 *Janeiro, Brazil*. J Virol, 2021.
- 545 11. NIH. 08.12.2021]; Available from: <https://www.covid19treatmentguidelines.nih.gov>.
- 546 12. Walsh, E.E., et al., *Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates*.  
547 N Engl J Med, 2020. **383**(25): p. 2439-2450.
- 548 13. Jackson, L.A., et al., *An mRNA Vaccine against SARS-CoV-2 - Preliminary Report*. N Engl J Med,  
549 2020. **383**(20): p. 1920-1931.
- 550 14. Wang, R., et al., *Vaccine-escape and fast-growing mutations in the United Kingdom, the United*  
551 *States, Singapore, Spain, India, and other COVID-19-devastated countries*. Genomics, 2021.  
552 **113**(4): p. 2158-2170.
- 553 15. Hoffmann, M., et al., *SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies*.  
554 Cell, 2021. **184**(9): p. 2384-2393 e12.
- 555 16. Addetia, A., et al., *Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in*  
556 *Humans during a Fishery Vessel Outbreak with a High Attack Rate*. J Clin Microbiol, 2020.  
557 **58**(11).
- 558 17. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection*  
559 *from symptomatic SARS-CoV-2 infection*. Nat Med, 2021. **27**(7): p. 1205-1211.
- 560 18. Earle, K.A., et al., *Evidence for antibody as a protective correlate for COVID-19 vaccines*.  
561 Vaccine, 2021. **39**(32): p. 4423-4428.
- 562 19. Huang, A.T., et al., *A systematic review of antibody mediated immunity to coronaviruses:*  
563 *antibody kinetics, correlates of protection, and association of antibody responses with severity*  
564 *of disease*. medRxiv, 2020.
- 565 20. Chmielewska, A.M., et al., *Immune response against SARS-CoV-2 variants: the role of*  
566 *neutralization assays*. NPJ Vaccines, 2021. **6**(1): p. 142.
- 567 21. Federal Office for Public Health Switzerland 08.12.2021]; Available from:  
568 [https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-](https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-83732.html)  
569 [83732.html](https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-83732.html).
- 570 22. Ulrich, L., et al., *Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta*. Nature,  
571 2021.
- 572 23. Ilmjarv, S., et al., *Concurrent mutations in RNA-dependent RNA polymerase and spike protein*  
573 *emerged as the epidemiologically most successful SARS-CoV-2 variant*. Sci Rep, 2021. **11**(1): p.  
574 13705.

- 575 24. Meyer, B., et al., *Validation of a commercially available SARS-CoV-2 serological immunoassay*.  
576 Clin Microbiol Infect, 2020. **26**(10): p. 1386-1394.
- 577 25. van der Straten, K., et al., *Mapping the antigenic diversification of SARS-CoV-2*. medRxiv, 2022:  
578 p. 2022.01.03.21268582.
- 579 26. Gidari, A., et al., *Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated,*  
580 *convalescent and P.1 infected*. J Infect, 2021. **83**(4): p. 467-472.
- 581 27. Faulkner, N., et al., *Reduced antibody cross-reactivity following infection with B.1.1.7 than with*  
582 *parental SARS-CoV-2 strains*. Elife, 2021. **10**.
- 583 28. Davis, C., et al., *Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern*  
584 *following vaccination*. PLoS Pathog, 2021. **17**(12): p. e1010022.
- 585 29. Rössler, A., et al., *SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from*  
586 *vaccinated and convalescent individuals*. medRxiv, 2021: p. 2021.12.08.21267491.
- 587 30. Hojjat Jodaylami, M., et al., *Cross-reactivity of antibodies from non-hospitalized COVID-19*  
588 *positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins*.  
589 Sci Rep, 2021. **11**(1): p. 21601.
- 590 31. Muik, A., et al., *Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2*  
591 *vaccine-elicited human sera*. Science, 2021. **371**(6534): p. 1152-1153.
- 592 32. Shen, X., et al., *Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351*. N Engl J Med, 2021.  
593 **384**(24): p. 2352-2354.
- 594 33. Mlcochova, P., et al., *SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion*.  
595 Nature, 2021. **599**(7883): p. 114-119.
- 596 34. Edara, V.V., et al., *Infection- and vaccine-induced antibody binding and neutralization of the*  
597 *B.1.351 SARS-CoV-2 variant*. Cell Host Microbe, 2021. **29**(4): p. 516-521 e3.
- 598 35. Skelly, D.T., et al., *Two doses of SARS-CoV-2 vaccination induce robust immune responses to*  
599 *emerging SARS-CoV-2 variants of concern*. Nat Commun, 2021. **12**(1): p. 5061.
- 600 36. Wang, P., et al., *Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization*. Cell  
601 Host Microbe, 2021. **29**(5): p. 747-751 e4.
- 602 37. Bates, T.A., et al., *Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine*  
603 *Immune Serum Samples*. JAMA, 2021.
- 604 38. Dejnirattisai, W., et al., *Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by*  
605 *post-immunisation serum*. medRxiv, 2021: p. 2021.12.10.21267534.
- 606 39. Cele, S., et al., *SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2*  
607 *elicited neutralization and requires ACE2 for infection*. medRxiv, 2021: p.  
608 2021.12.08.21267417.
- 609 40. Wilhelm, A., et al., *Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera*  
610 *and monoclonal antibodies*. medRxiv, 2021: p. 2021.12.07.21267432.
- 611 41. Smith, D.J., et al., *Mapping the antigenic and genetic evolution of influenza virus*. Science,  
612 2004. **305**(5682): p. 371-6.
- 613 42. Acevedo, M.L., et al., *Infectivity and immune escape of the new SARS-CoV-2 variant of interest*  
614 *Lambda*. medRxiv, 2021: p. 2021.06.28.21259673.
- 615 43. Xie, X., et al., *Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated*  
616 *vaccine-elicited antibodies*. Zool Res, 2021. **42**(6): p. 789-791.
- 617 44. Uriu, K., et al., *Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine*  
618 *Serum*. N Engl J Med, 2021. **385**(25): p. 2397-2399.
- 619 45. Liu, H., et al., *The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to*  
620 *escape vaccines*. bioRxiv, 2021.
- 621 46. Collier, D.A., et al., *Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies*.  
622 Nature, 2021. **593**(7857): p. 136-141.
- 623 47. Greaney, A.J., et al., *Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding*  
624 *domain that affect recognition by polyclonal human plasma antibodies*. Cell Host Microbe,  
625 2021. **29**(3): p. 463-476 e6.



- 626 48. Andreano, E., et al., *SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19*  
627 *convalescent plasma*. bioRxiv, 2020.
- 628 49. Liu, Z., et al., *Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that*  
629 *attenuate monoclonal and serum antibody neutralization*. bioRxiv, 2021.
- 630 50. Weisblum, Y., et al., *Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants*.  
631 *Elife*, 2020. **9**.
- 632 51. Starr, T.N., et al., *Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals*  
633 *Constraints on Folding and ACE2 Binding*. *Cell*, 2020. **182**(5): p. 1295-1310 e20.
- 634 52. Garcia-Beltran, W.F., et al., *mRNA-based COVID-19 vaccine boosters induce neutralizing*  
635 *immunity against SARS-CoV-2 Omicron variant*. medRxiv, 2021.
- 636 53. Doria-Rose, N.A., et al., *Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape*  
637 *from Neutralizing Antibodies*. medRxiv, 2021.
- 638 54. Nemet, I., et al., *Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection*.  
639 medRxiv, 2021: p. 2021.12.13.21267670.
- 640 55. Yu, X., et al., *Enhanced neutralization against SARS-CoV-2 by vaccine booster exhibits*  
641 *reduction of Omicron variant*. medRxiv, 2021: p. 2021.12.17.21267961.
- 642 56. Eggink, D., et al., *Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in*  
643 *vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December*  
644 *2021*. medRxiv, 2021: p. 2021.12.20.21268121.
- 645 57. Brown, E.L. and H.T. Essigmann, *Original Antigenic Sin: the Downside of Immunological*  
646 *Memory and Implications for COVID-19*. *mSphere*, 2021. **6**(2).
- 647 58. Karuna, S., et al., *Neutralizing antibody responses over time in demographically and clinically*  
648 *diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A*  
649 *cohort study*. *PLoS Med*, 2021. **18**(12): p. e1003868.
- 650 59. Zahradnik, J., et al., *Receptor binding and escape from Beta antibody responses drive Omicron-*  
651 *B.1.1.529 evolution*. bioRxiv, 2021: p. 2021.12.03.471045.
- 652 60. Yang, W. and J. Shaman, *SARS-CoV-2 transmission dynamics in South Africa and*  
653 *epidemiological characteristics of the Omicron variant*. medRxiv, 2021: p.  
654 2021.12.19.21268073.
- 655 61. Gaebler, C., et al., *Evolution of antibody immunity to SARS-CoV-2*. *Nature*, 2021. **591**(7851): p.  
656 639-644.

657 **Supplementary data**

658 **Table S1.** Patient sample information from which virus isolates used in this study were obtained.

659 **Figure S1.** Neutralizing antibody titers of each pre-VOC convalescent individual (P=plasma sample, S=  
660 serum sample).

661 **Figure S2.** Neutralizing antibody titers of each Alpha convalescent individual (S= serum sample).

662 **Figure S3.** Neutralizing antibody titers of each Beta convalescent individual (S= serum sample).

663 **Figure S4.** Neutralizing antibody titers of each Gamma convalescent individual (S= serum sample).

664 **Figure S5.** Neutralizing antibody titers of each Delta convalescent individual (S= serum sample).

665 **Figure S6.** Neutralizing antibody titers of each post-vaccination individual with double vaccination)  
666 (P=plasma sample, S= serum sample).

667 **Figure S7.** Neutralizing antibody titers of each post-vaccination individual with prior infection followed  
668 by double vaccination (P=plasma sample).

669 **Figure S8.** Neutralizing antibody titers of each post-vaccination individual with Delta breakthrough  
670 infection (S= serum sample).

671 **Figure S9.** Neutralizing antibody titers of each post-vaccination individual with Omicron breakthrough  
672 infection (S= serum sample).

673

674

	<b>B.1</b>	<b>Alpha</b>	<b>Beta</b>	<b>Gamma</b>	<b>Delta</b>	<b>Zeta</b>	<b>Omicron</b>
<b>Name</b>	hCoV-19/Switzerland/GE-SNRCI-29943121/2020	hCoV-19/Switzerland/2012212272/2020	hCoV-19/Switzerland/GE-33128281/2021	hCoV-19/Switzerland/GE-33115015/2021	hCoV-19/Switzerland/GE-33896105/2021	hCoV-19/Switzerland/GE-32966260/2021	hCoV-19/Switzerland/VD-HUG-36221084/2021
<b>GISAID accession ID</b>	EPI_ISL_414019	EPI_ISL_2131446	EPI_ISL_981782	EPI_ISL_981707	EPI_ISL_1811202	EPI_ISL_897700	EPI_ISL_7605546
<b>Clade</b>	G	GRY	GH	GR	GK	G	GRA
<b>Pango lineage</b>	B.1	B.1.1.7	B.1.351	P.1	AY.122	P.2	BA.1

**Table S1.** Patient sample information from which virus isolates were obtained

Figure S1.

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.21263491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).


















Figure S1.

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.21268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




















Figure S1.


S65




S67



S68



S69



medRxiv preprint doi: <https://doi.org/10.1101/2021.12.28.21263491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



Figure S2.

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.21268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).















Figure S3.

medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.22126849>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).











Figure S4.

medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.2208491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).













Figure S5.

medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.22263491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).













Figure S6.

medRxiv preprint doi: <https://doi.org/10.1101/2021.12.28.21268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



















Figure S6.

P104



medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.22268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



Figure S7.

medRxiv preprint doi: <https://doi.org/10.1101/2021.12.21.21268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).











Figure S8.


S130




S131



S132







S133



medRxiv preprint doi: <https://doi.org/10.1101/2022.01.12.22263491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

Figure S9.



medRxiv preprint doi: <https://doi.org/10.1101/2021.12.10.21268491>; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).